[Edaily Reporter Hyera Lee ] #DongBang Medical Co., Ltd. announced on the 3rd that it recently participated in “The Aesthetic Show 2026,” an aesthetic medicine conference held in Las Vegas, USA, and introduced its own brand, Miracu. The medical thread “Miracu.” (Photo courtesy of DongBang Medical Co., Ltd.) Miracu is a cannula-integrated polydioxanone (PDO) thread product that encompasses a diverse lineup of threads—including Mono, Screw, and Cog—as well as dedicated cannulas. It is the first brand in the soft tissue adhesion product category to receive U.S. Food and Drug Administration (FDA) 510(k) Class II clearance. DongBang Medical Co., Ltd., the world’s largest manufacturer of cannulas and PDO threads, showcased its Miracu cannula and PDO thread product line at the event under the slogan “See Everything. Miss Nothing,” emphasizing precise visibility and safety. In particular, the company unveiled new needles and syringes designed specifically for skin boosters for the first time at this event. The specialized needle design, which aids in precise procedures, and the syringe’s ease of use drew significant interest from medical professionals in attendance. DongBang Medical Co., Ltd. conducted live demonstrations of Miracu products and provided training on procedural techniques for conference participants. A DongBang Medical Co., Ltd. representative stated, “Through this participation, we aimed to convey both the reliability of our FDA-approved, clinically validated products and our expertise in precise procedures to medical professionals in the U.S. market.”
#NEXTBIOMEDICAL CO., LTD., a company specializing in innovative medical devices, has been named to the Korea Exchange’s “KOSDAQ Rising Star” list for the second consecutive year, once again demonstrat…
Portable X-ray manufacturer Remedi saw its stock price surge after reporting explosive earnings growth. The company is expanding rapidly not only in South Korea but also overseas, raising expectations…
With the U.S. Food and Drug Administration (FDA) approving a new oncolytic virus therapy for the first time in about 11 years, attention in South Korea is turning to SillaJen, Inc.(215600), which is d…